Pharmacoepidemiology

Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
Antonio Gonzalez Perez, David Vizcaya, Maria E Sáez, Marcus Lind, Luis A Garcia Rodriguez

BMJ Open Diabetes Research and Care Jan 2023, 11 (1) e003072; DOI: 10.1136/bmjdrc-2022-003072
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
Richeek Pradhan, Oriana H Y Yu, Robert W Platt, Laurent Azoulay

BMJ Open Diabetes Research and Care Nov 2023, 11 (6) e003550; DOI: 10.1136/bmjdrc-2023-003550
Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
Wajd Alkabbani, Arsene Zongo, Jasjeet K Minhas-Sandhu, Dean T Eurich, Baiju R Shah, Mhd Wasem Alsabbagh, John-Michael Gamble

BMJ Open Diabetes Research and Care Dec 2021, 9 (2) e002496; DOI: 10.1136/bmjdrc-2021-002496
Antidiabetic medication use during pregnancy: an international utilization study
Carolyn E Cesta, Jacqueline M Cohen, Laura Pazzagli, Brian T Bateman, Gabriella Bröms, Kristjana Einarsdóttir, Kari Furu, Alys Havard, Anna Heino, Sonia Hernandez-Diaz, Krista F Huybrechts, Øystein Karlstad, Helle Kieler, Jiong Li, Maarit K Leinonen, Hanne L Gulseth, Duong Tran, Yongfu Yu, Helga Zoega, Ingvild Odsbu

BMJ Open Diabetes Research and Care Nov 2019, 7 (1) e000759; DOI: 10.1136/bmjdrc-2019-000759
Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus
Ting-Ying Huang, Carla Rodriguez-Watson, Tongtong Wang, Shawna R Calhoun, James Marshall, Jillian Burk, Young Hee Nam, Aaron B Mendelsohn, Aziza Jamal-Allial, Robert T Greenlee, Mano Selvan, Pamala A Pawloski, Cheryl N McMahill Walraven, Ashish Rai, Sengwee Toh, Jeffery S Brown

BMJ Open Diabetes Research and Care Dec 2022, 10 (6) e002916; DOI: 10.1136/bmjdrc-2022-002916
Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling
Masato Takeuchi, Masahito Ogura, Nobuya Inagaki, Koji Kawakami

BMJ Open Diabetes Research and Care Jun 2022, 10 (3) e002636; DOI: 10.1136/bmjdrc-2021-002636
Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
Gian Paolo Fadini, Mayur Sarangdhar, Angelo Avogaro

BMJ Open Diabetes Research and Care Jan 2018, 6 (1) e000475; DOI: 10.1136/bmjdrc-2017-000475
Correlates of second-line type 2 diabetes medication selection in the USA
Ronald T Ackermann, Amisha Wallia, Matthew J O'Brien, Raymond Kang, Andrew Cooper, Margaret R Moran, David T Liss

BMJ Open Diabetes Research and Care Aug 2017, 5 (1) e000421; DOI: 10.1136/bmjdrc-2017-000421
Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR)
Nils Ekström, Ann-Marie Svensson, Mervete Miftaraj, Karolina Andersson Sundell, Jan Cederholm, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir

BMJ Open Diabetes Research and Care Mar 2015, 3 (1) e000059; DOI: 10.1136/bmjdrc-2014-000059

Log in using your username and password

Main menu

Log in using your username and password

You are here

Pharmacoepidemiology